COLIBRI HEART VALVE LLC v. MEDTRONIC COREVALVE, LLC - Before Taranto, Hughes, and Stoll. Appeal from the United States District Court for the Central District of California. The Federal Circuit reversed a $106 million...more
In Dolby Laboratories Licensing Corporation V. Unified Patents, LLC, Appeal No. 23-2110, the Federal Circuit held that a patent owner lacks Article III standing to appeal an inter partes review decision on patentability when...more
ALNYLAM PHARMACEUTICALS, INC. v. MODERNA, INC. - Before Taranto, Chen, and Hughes. Appeal from the United States District Court for the District of Delaware. Once the high threshold for lexicography is met, there must be a...more
6/30/2025
/ Appeals ,
CAFC ,
Claim Construction ,
Intellectual Property Litigation ,
Life Sciences ,
Moderna Inc. ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents
AZURITY PHARMACEUTICALS, INC. v. ALKEM LABORATORIES LTD. Before Murphy, Moore, and Chen. Appeal from the United States District Court for the District of Delaware. Arguments and amendments made during prosecution of a parent...more
Limits of Inherent Anticipation in Product-by-Process Claims - In Restem, LLC v. Jadi Cell, LLC, Appeal No. 23-2054, the Federal Circuit held that inherency in product-by-process claims requires the prior art to inevitably...more
In Honeywell International Inc. v. 3G Licensing, S.A., Appeal No. 23-1354, the Federal Circuit held that under the obviousness standard of 35 U.S.C. § 103, the motivation to modify prior art does not need to be the same as...more
2/10/2025
/ Appeals ,
Claim Construction ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Obviousness ,
Patent Applications ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents
Bound to Happen: Inherent Property Leaves No Question of Reasonable Expectation of Success - In Cytiva Bioprocess R&D Ab v. Jsr Corp., Appeal No. 23-2074, the Federal Circuit held that a claim limitation merely reciting an...more
1/10/2025
/ Appeals ,
Attorney's Fees ,
Claim Construction ,
Infringement ,
Inter Partes Review (IPR) Proceeding ,
Obviousness ,
Patent Invalidity ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Summary Judgment
Failure to Obtain Advice of a Third Party Is Not Evidence of Willfulness - In Provisur Technologies, Inc., v. Weber, Inc., Appeal No. 23-1438, the Federal Circuit held that patentees cannot use an accused infringer’s failure...more
11/14/2024
/ Claim Construction ,
Damages ,
ETSI ,
FRAND ,
Infringement ,
Injunctions ,
Intellectual Property Protection ,
Motion to Dismiss ,
Patent Infringement ,
Patents ,
Reversal ,
Third-Party
In Natera, Inc v. Neogenomics Laboratories, Inc., Appeal No. 24-1324 the Federal Circuit held that preliminary injunction may be valid if a substantial question of invalidity was not raised, even if the asserted patent is...more
8/6/2024
/ Background Checks ,
Claim Construction ,
Estoppel ,
Ex Parte ,
Inter Partes Review (IPR) Proceeding ,
Limited Liability Company (LLC) ,
Patent Invalidity ,
Patent-Eligible Subject Matter ,
Patents ,
Preliminary Injunctions ,
Prior Art ,
Public Disclosure ,
Public Interest ,
USPTO
Defining Indefiniteness: When Are Claim Limitations Contradictory?
In Maxell, Ltd., v. Amperex Technology Limited, Appeal No. 23-1194, the Federal Circuit held that two claim limitations are not contradictory if they...more
The Outcome of the PTAB’s Analysis May Determine Whether the PTAB Engaged in Claim Construction -
In Google LLC v. Ecofactor, Inc., Appeal No. 22-1750, the Federal Circuit held that the outcome of the PTAB’s analysis of...more
3/5/2024
/ Administrative Procedure Act ,
Claim Construction ,
Google ,
Intellectual Property Protection ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Philip Morris ,
Prior Art
Federal Circuit Orders District Court to Consider Extrinsic Evidence in Claim Construction -
In Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., Appeal No. 22-1889, the Federal Circuit held that where a...more
12/5/2023
/ Article III ,
Claim Construction ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Life Sciences ,
Mylan Pharmaceuticals ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Purdue Pharma ,
Standing
Substantial Evidence in Determining Obviousness -
In Schwendimann v. Neenah, Inc, Appeal No. 22-1335, the Federal Circuit held that the PTAB’s finding on obviousness is supported by substantial evidence that a skilled...more
IPR Petitioners Must Be Permitted to Respond to Claim Constructions First Proposed in Patent Owner Response -
In Axonics, Inc. v. Medtronic, Inc., Appeal No. 22-1532, the Federal Circuit held that where a patent owner in...more
9/20/2023
/ Claim Construction ,
Ex Parte ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Ownership ,
Patent Term Adjustment ,
Patent Term Extensions ,
Patent Trial and Appeal Board ,
Patents ,
USPTO
Claims With Clerical Errors Can Be Judicially Corrected and Willfully Infringed -
In Pavo Solutions LLC v. Kingston Technology Company, Inc., Appeal No. 21-1834, the Federal Circuit held that a court can correct obvious...more
Somebody’s Wrong: PTAB Must Resolve Conflicting Factual Testimony During IPR -
In Google LLC v. IPA Technologies Inc., Appeal No. 21-1179, the Federal Circuit held that, for purposes of determining whether a reference was...more
6/20/2022
/ Appointments Clause ,
Arthrex Inc v Smith & Nephew Inc ,
Claim Construction ,
Constitutional Challenges ,
Federal Vacancies Reform Act ,
Google ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents
A Construction That Eliminates the Entire Scope of Dependent Claims Should Be Avoided -
Littelfuse, Inc. v. Mersen USA Ep Corp., Appeal No. 21-2013, the Federal Circuit vacated a claim construction that violated the doctrine...more
Claim Limitation Not Disclosed by Any Reference but Disclosed by “Proposed Combination” of References Is Obvious -
In Hoyt Augustus Fleming v. Cirrus Design Corporation, Appeal No. 21-1561, the Federal Circuit held that a...more
4/5/2022
/ Anticipation ,
Claim Construction ,
Claim Limitations ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Motion to Amend ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Sua Sponte ,
Substitute Claims
Ordered To Agree: Binding Settlement Agreement Provision Found Despite Absence of Singular, Executed Agreement -
In Plasmacam, Inc. v. Cncelectronics, LLC Appeal No. 21-1689, the Federal Circuit held that an agreement on...more
3/22/2022
/ Appeals ,
Binding Agreements ,
Broadest Reasonable Interpretation Standard ,
Claim Construction ,
Contract Terms ,
Estoppel ,
Inter Partes Review (IPR) Proceeding ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Preliminary Injunctions ,
Prior Art ,
Settlement Agreements
避而不谈可能支持否定性权利要求限定 -
在 Novartis Pharmaceuticals 诉 Accord Healthcare Inc. 一案（上诉案件编号：21- 1070）中，联邦巡回上诉法院认为，一项对药物“速效剂量”避而不谈的专利申请，为要求不存在此类剂量的否定 性权利要求限制提供了书面说明支持。
...more
2/10/2022
/ Claim Construction ,
Indefiniteness ,
Intellectual Property Protection ,
Novartis ,
Patent Applications ,
Patent Examinations ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents
記述がないことがクレームの否定的限定のサポートと解釈できる場合がある
Federal Circuit は、Novartis Pharmaceuticals v. Accord Healthcare Inc. (Appeal No. 21-1070) に おいて、薬剤の「初回負荷用量」についての記述がない特許出願は、そのような用量がないことを要 求するクレームの否定的限定に記述によるサポートを提供していることになると判示した。
...more
2/10/2022
/ Claim Construction ,
Indefiniteness ,
Intellectual Property Protection ,
Novartis ,
Patent Applications ,
Patent Examinations ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents
January 2022 Federal Circuit Newsletter (Japanese) January 2022 Federal Circuit Newsletter (Chinese) Silence May Support Negative Claim Limitation In Novartis Pharmaceuticals v. Accord Healthcare Inc. Appeal No. 21-1070, the...more
2/9/2022
/ Claim Construction ,
Indefiniteness ,
Intellectual Property Protection ,
Novartis ,
Patent Applications ,
Patent Examinations ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents
District Court’s Pleading Standard Returns an Error Code in PS4 Battle -
In Bot M8 LLC v. Sony Corporation Of America, Appeal No. 20-2218, the Federal Circuit held that the district court’s view that infringement...more
8/18/2021
/ Amended Complaints ,
Claim Construction ,
Failure To State A Claim ,
Gaming ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pleading Standards ,
Prior Art ,
Qualcomm ,
Sony ,
Sua Sponte
Bulk-Filed Patent Applications Claiming Distant Priority Trigger Prosecution Laches -
In Hyatt v. Hirshfeld, Appeal No. 18-2390, the Federal Circuit held that the PTO met its burden to prove prosecution laches for bulk-filed...more
7/28/2021
/ Amazon Marketplace ,
Antitrust Provisions ,
Apple ,
Assignor Estoppel ,
Claim Construction ,
Compensation ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Inventions ,
Laches ,
NCAA ,
Patent Applications ,
Patent Infringement ,
Patents ,
Prior Art ,
Standalone Authority ,
Subject Matter Jurisdiction ,
USPTO ,
Venue
Corresponding Structure Snafu: Lack of Algorithm Renders Claims Indefinite -
In Rain Computing, Inc. v. Samsung Electronics Co. Ltd., Appeal No. 20-1646, the Federal Circuit held that the structure for performing a...more
4/27/2021
/ Algorithms ,
Claim Construction ,
Doctrine of Equivalents ,
Estoppel ,
Indefiniteness ,
Means-Plus-Function ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents